No description available.

No description available.

Mosses are small avascular bryophytes with a haploid dominant gametophyte and a diploid sporophyte stage. The gametophyte cells are single layered and lack a protective cuticle, which is the first line of defense in vascular plants. These factors would render them highly susceptible to stress but on the contrary, mosses have flourished on land for the past 450 million years with tolerance to both abiotic and biotic stress. Occurrence of unique lipids in bryophytes was considered as an adaptive means to survive harsh terrestrial condition. A recent study identified a lipid metabolite, anandamide in the Physcomitrella patens. Anandamide (NAE 20:4) belongs to a group of fatty acid ethanolamides or N –acylethanolamines (NAEs). In eukaryotes, NAEs were shown to play an important role in mediating stress responses. In plants, NAE 14:0 has been implicated in biotic stress response; its levels increased up to 50-fold in elicitor-treated tobacco plants, along with induction of defense gene expression and inhibition of alkalization. In animals anandamide acts as an endocannabinoid ligand and mediates several physiological responses including stress. This study aims to use P. patens as the model system because of its available genomic database and prior studies on biotic stress, to examine if NAE 20:4 contributes to their ability to tolerate biotic stress. It is hypothesized that the occurrence of anandamide will play a role in mediating biotic stress tolerance in P. patens. To test this hypothesis, three specific aims are proposed. They are to determine the effect of 1) elicitor-treatment on NAE and fatty acid profile in the moss, 2) anandamide on elicitor-induced morphological and physiological changes in the moss and 3) anandamide on elicitor-induced defense gene expression in moss. Mosses utilize similar defense mechanisms as flowering plants and disease symptoms can easily be studied using microscopy because of their haploid dominant gametophyte stage with monolayer cells. The induction of defense gene expression will be studied by quantitative PCR and changes in lipid profile by selective lipidomics. This study is expected to provide novel insights into the role of anandamide in early land plants, specifically in response to biotic stress.

No description available.

No description available.

Improving crop yield by generating stress tolerant plants is the enduring objective of this research. A small class of bioactive fatty acid derivatives, N-acylethanolamines (NAEs), including anandamide (NAE 20:4), an endocannabinoid receptor ligand, affects a wide range of physiological and behavioral functions in animals. In plants, NAEs to the exclusion of anandamide are found to be ubiquitous and abundant in seed tissues and are shown to be involved in mediating abscisic acid (ABA) -dependent or -independent stress responses. Early land plants such as Physcomitrella patens (moss) have been shown to tolerate abiotic stresses. We hypothesized that NAEs are involved in mediating stress responses in moss. Gas chromatography-mass spectrometry was employed in NAE detection and quantification in moss. Selective lipidomic approach revealed novel NAE metabolites. The endocannabinoid receptor ligand anandamide and its precursor molecules were detected and quantified. Exogenous treatment of NAE 12:0, NAE 20:4 and ABA showed a growth inhibitory effect for all three metabolites. NAE 20:4 was more potent than NAE 12:0 to degrees similar to the plant hormone ABA. In silico analyses of NAE catabolizing enzyme fatty acid amide hydrolase from Arabidopsis showed eight putative FAAH candidates in this moss. Candidates showed high similarities with plants as well as animal FAAH proteins. Primers specific to NAE pathway genes have been designed for expression analysis. Our recent identification of the ligand NAE 20:4 in this moss, provides us with a unique opportunity to address if 1) early land plants, such as mosses, retained the endocannabinoid signaling mechanism that is akin to animals but not to plants and 2) if such distinctive NAE profile and mechanism by which it may function in moss plant is responsible, in part, for their natural ability to resist high temperatures, dehydration, osmotic and salt stresses. Insights into unique lipids composition and signaling pathways that mosses acquire naturally, during their successful transition from water to land, may lead to development of tools necessary to enhance abiotic stress tolerance in vegetative tissues of higher plants and thus contribute to improvement of crop productivity.

Considerable evidence supports anandamide (AEA) as an important mediator in the regulation of nausea and vomiting. The present study investigates the effect of inhibiting a protein reported to mediate AEA transport, FLAT (FAAH-1-like AEA transporter), on nausea and vomiting and the neural correlates of AEA regulated nausea in the visceral insular cortex (VIC). The systemic administration of the AEA transport inhibitor ARN272 was evaluated in LiCl-induced conditioned gaping in rats, and vomiting in shrews. The effect of intra-cranial administration of ARN272 into the VIC was also investigated using LiCl-induced conditioned gaping in rats. Systemic administration of ARN272 dose-dependently suppressed LiCl-induced conditioned gaping in rats, and was reversed by CB1 receptor antagonism with SR141716. Systemic administration of ARN272 also attenuated vomiting in shrews. Delivery of ARN272 into the VIC produced no effect on LiCl-induced conditioned gaping in rats. These results suggest that preventing the cellular reuptake of AEA through transport inhibition tonically activates CB1 receptors to regulate toxin-induced nausea, but that this is not AEA regulated within the VIC. / This research was supported by grants from the Natural Sciences and Engineering Research Council of Canada (NSERC-92057) to LAP.

Le système endocannabinoïde (SEC) est composé : de deux neurotransmetteurs principaux qui sont l’anandamide (AEA) et le 2-arachidonoylglycerol (2-AG), de deux enzymes de catabolisme associées, respectivement la Fatty Acid Amide Hydrolase (FAAH) et la Monoacylglycerol Lipase (MAGL); et de deux récepteurs principaux qui sont les récepteurs cannabinoïdes de type 1 (CB1) et de type 2 (CB2). Le SEC exerce un rôle critique dans le contrôle des propriétés récompensantes des substances addictives, dont la nicotine. Cependant, le SEC possède un mode de fonctionnement biphasique et complexe. Par exemple, alors que les propriétés renforçantes et incitatrices de la nicotine sont diminuées par le blocage aigu des récepteurs CB1, le comportement de recherche de nicotine peut également être bloqué par l’augmentation aigüe du tonus endocannabinoïde (eCB). Par ailleurs, les essais cliniques suggèrent que le traitement chronique avec l’antagoniste des récepteurs CB1 produit des effets secondaires liés à l’état émotionnel des fumeurs abstinents. Ces résultats indiquent clairement, que l’utilisation optimale de la pharmacologie cannabinoïde pour le traitement chronique du sevrage tabagique reste compliquée et encore mal maitrisée. Le but de ce travail de thèse était d’abord de préciser le rôle des récepteurs CB1 dans le contrôle aigu des propriétés addictives de la nicotine, puis de déterminer le rôle de l’AEA dans le contrôle à long terme des propriétés incitatives de la nicotine. L’hypothèse générale était que la prise volontaire de nicotine, puis le traitement chronique avec un inhibiteur de la FAAH, produiraient une augmentation de l’AEA persistante chez le rat abstinent. Celle-ci aurait 2 conséquences : d’une part la réduction du comportement de recherche de nicotine, et d’autre part le développement d’un état anxieux généralisé indépendant de la transmission via les récepteurs CB1. Pour tester cette hypothèse, des rats ont été exposés à l’auto-administration intraveineuse de nicotine pendant 8 semaines puis mis en abstinence pendant 8 semaines. Pendant cette seconde période, les animaux ont été injectés quotidiennement avec un inhibiteur de la FAAH et nous avons caractérisé le comportement de recherche de nicotine et l’état émotionnel de ces rats. Les résultats ont d’abord montré une grande variabilité inter-individuelle dans la prise volontaire de nicotine, nous avons pu identifier des rats à faible consommation (« low consumers ») et des rats à forte consommation (« high consumers »). Il semble que l’inhibition chronique de la FAAH bloque significativement la rechute induite par la drogue et par les stimuli environnementaux chez les « low consumers » abstinents, et reste sans conséquence sur l’état émotionnel des rats. En revanche chez les « high consumers », l’inhibition de la FAAH bloque uniquement la rechute induite par la nicotine et ces animaux restent sensibles aux effets précipitants des stimuli environnementaux. Par ailleurs, ils développent un état anxieux modéré qui n’est pas bloqué par le traitement avec un antagoniste des récepteurs CB1. Ces données suggèrent donc que chez les « high consumers » abstinents, il existe un excès d’AEA qui cible des circuits différents pour moduler les propriétés incitatrices de la nicotine et l’anxiété. En conclusion, cette étude montre que l’inhibiteur de FAAH pourrait être un outil thérapeutique adapté au traitement de l’addiction à la nicotine si l’on prend en compte la variabilité inter-individuelle rencontrée dans la consommation abusive de nicotine. / The endogenous cannabinoid system, also called the endocannabinoid system (ECS), comprises two principal neurotransmitters: anandamide (AEA) and 2-arachidonoylglycerol (2-AG), whose specific degradation enzymes are fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. Both AEA and 2-AG bind to cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. The ECS is a key element for the expression of both natural and pharmacological reward processes, including nicotine reward. However, the biphasic and complex nature of the ECS renders it a difficult system to study. For example, although acute blockade of CB1 receptors reduces the reinforcing and incentive properties of nicotine, it has also been demonstrated that an acute increase of AEA (CB1 agonist) blocks nicotine-seeking behavior. The aim of the present work is twofold: first, to better characterize the neural substrates through which CB1 receptors regulate the voluntary intake of nicotine; and second, to determine the effect of a chronic increase of AEA tone in nicotine-abstinent rats on i) their persistent motivation for nicotine and ii) their affective phenotype. The hypothesis tested here is that chronic treatment with a FAAH inhibitor after chronic exposure to nicotine will induce a large and persistent increase of AEA during a period of nicotine abstinence. Subsequently, high levels of AEA would reduce the incentive properties of nicotine and nicotine-related stimuli, thus reducing nicotine seeking, and it would also promote high levels of anxiety which might be CB1-independent. In order to test this hypothesis, rats were exposed to nicotine (60 µg/kg/0.1 ml) intravenous self-administration (IVSA) for 8 weeks, after which they remained nicotine-free until the end of the experiment. During the period of abstinence, animals were injected daily with a FAAH inhibitor for 8 weeks (URB597, 0.3 mg/kg i.p.), and both their motivation for nicotine and their affective profile were assessed. Animals were classified into “low consumers” and “high consumers” since a high degree of inter-individual variability was observed in the total amount of nicotine taken over the 8-week IVSA period. We show that in the “low consumers”, chronic FAAH inhibition dramatically reduces nicotine seeking behavior and cue-related incentive salience, and does not induce anxiety-related side-effects during abstinence. In the “high consumers”, however, chronic FAAH inhibition reduces nicotine seeking but not cue-related incentive salience, and causes an increase in anxiety-like behaviors that are not blocked by a CB1 receptor antagonist. These data suggest that in the population of “high consumers”, the effects of increased AEA tone on motivation and anxiety might be mediated by different neuronal circuits. In conclusion, this study demonstrates the potential of chronic FAAH inhibition as an important therapeutic tool for the treatment of nicotine addiction in subjects with a moderate nicotine intake.

While there is currently active debate over possible therapeutic applications of marijuana and cannabis-based compounds, consistently their primary drawbacks have been the psychoactive properties, dependence, and abuse potential. Prolonged administration of ∆9-tetrahydrocannabinol (THC), the primary psychoactive constituent in marijuana, demonstrates both tolerance and physical withdrawal in both preclinical and clinical studies. Repeated THC administration also produces CB1 receptor adaptations in the form of reduced activation of receptors, along with a downregulation of membrane surface receptors, in many brain regions involved in THC-associated behaviors. The increased need for drug to maintain therapeutic effects, and a withdrawal syndrome following discontinuation of use, are common risk factors in drugs of abuse. Recently, compounds have been developed that prolong the availability of the major naturally occurring endogenous cannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), through inhibition of their catabolic breakdown by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. The overall objectives of this research are to elucidate the physiologic roles of these two endogenous ligands and to determine if either can produce beneficial therapeutic effects without negative cannabis-like CNS effects. Therefore, we tested the impact of acute and prolonged blockade of FAAH and MAGL on a variety of cannabinoid-mediated behaviors and on precipitated cannabinoid withdrawal. Despite that acute blockade of FAAH and MAGL produce similar efficacy in reducing nociceptive responses, and both can reduce THC-induced somatic withdrawal, sustained blockade of these enzymes leads to remarkably different adaptations in CB1 receptor functioning. Namely, prolonged elevations in brain 2-AG leads to marked antinociceptive tolerance, cross-tolerance to exogenous cannabinoid agonists, and physical dependence. In contrast, sustained elevations in brain anandamide continues to dampen pain responses without apparent signs of physical withdrawal, loss of CB1 receptor activation as measured by [35S]GTPγS, or receptor downregulation as measured by [3H]CP,55940. These results suggest that chronic 2-AG elicits greater compensatory changes in CB1 receptor functions than anandamide. With similar efficacy in most therapeutic endpoints tested, and evidence of reduced impact on long-term function of the endocannabinoid system, these results distinguish FAAH as a more promising therapeutic target to treat pain and other conditions than MAGL.

Cannabinoid agonists, including marijuana containing delta-9-tetrahydrocannabinol (THC), are found rewarding by humans. In addition to human self-reports and experimental studies that show marijuana is rewarding, contributions from preclinical studies also have implicated cannabinoid receptors in reward-motivated behavior. One way to assess these preclinical effects of cannabinoids is intracranial self-stimulation (ICSS), where an animal performs a response to receive electrical stimulation of a specific brain area or circuit known to be involved in reward. Drugs of abuse, such as psychomotor stimulants, facilitate responding for ICSS. While a few studies have shown facilitating effects of cannabinoids in rats, several have shown the opposite effect, and no studies so far have evaluated cannabinoids in mouse ICSS. Furthermore there are no studies evaluating specific inhibitors of endocannabinoid catabolic enzymes in ICSS in any species. In these studies we assessed the cannabinoid agonist THC, as well as the fatty acid amide hydrolase (FAAH) inhibitor, PF-3845, the monoacylglycerol lipase (MAGL) inhibitor JZL184, and the combined FAAH/MAGL inhibitor SA-57 in ICSS of the medial forebrain bundle in C57BL/6 mice. Additionally, we assessed the psychomotor stimulant cocaine as a positive control to facilitate ICSS. These studies were complimented with spontaneous locomotor activity and food-maintained operant experiments to assess the sensitivity of ICSS to cannabinoids. Additionally, brain endocannabinoid levels were measured in brain regions associated with the mesolimbic system after enzyme inhibitor treatments. THC, JZL184, and SA-57 all produced time-dependent reductions in ICSS that were mediated through CB1 receptors, as they were blocked by pre-treatment with the CB1 antagonist rimonabant, but not with the CB2 antagonist SR144528. PF-3845 also reduced ICSS, but did so independent of CB1 and CB2 receptors, and only with one dose (30.0 mg/kg) that has not been assessed previously in vivo. We showed that ICSS was more sensitive to the rate-reducing effects of cannabinoids than other measures of behavior with motor components including spontaneous locomotor activity and operant nose-poking for food, and that the reduction of ICSS produced by both JZL184 and SA-57 is accompanied by increases in 2-AG in mesolimbic brain areas. Thus, cannabinoids do not facilitate ICSS in C57BL/6 mice over a range of doses and pre-treatment times, similar to most studies with rats. These data suggest that cannabinoids may produce rewarding effects through non-mesolimbic areas of the brain.